久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Cleveland BioLabs 
BioLabs主要從事藥物發現和開發業務
Established in 2003, Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications.

The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.

CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

The Company has a strong intellectual property position covering its drug discovery technology and products, including 20 families of pending patents.